[ET Net News Agency, 9 November 2021] TOT BIOPHARM International Company Limited
(01875) said during the nine months ended 30 September 2021, the group's revenue increased
by 96.4% year-on-year to RMB36,225,000, mainly attributable to the increase in CDMO/CMO
business.
Net loss was RMB177.9 million, compared to the loss of RMB211.08 million of the same
period last year. (RC)